NYSE:PFE

Pfizer Inc (PFE)

24.10
-0.63 (2.53%)
as of Jun 24, 2026, 7:36:27 pm Market Open.
581 watching
0
Investor Insights
star iconJun 24, 2026, 12:00 am

This summary was created by AI, based on 29 opinions in the last 12 months.

Pfizer Inc (PFE) is facing significant challenges as it navigates a patent cliff and the subsequent impacts on revenue after its COVID-19 vaccine boom. Many analysts express concerns about the lack of earnings momentum and the uncertain prospects for new blockbuster drugs in its pipeline. Despite these challenges, PFE maintains an attractive dividend yield ranging from 6% to 7% that provides a steady income for shareholders. The company's strategy includes cost-cutting measures and acquiring smaller companies to refill its drug development pipeline. However, the stock typically trades at a low price-to-earnings ratio, indicating a lack of confidence in future growth, with multiple experts suggesting a need for patience and a potential wait for positive catalysts to drive price appreciation.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
NVO
BUY
A great long term hold for growth. Strong pipeline.
DON'T BUY
Prefers Glaxco Smith Klein.
BUY
Prefers this and J&J over Merk. Will eventually give a 15/20% return.
BUY
At a good price. Have a good drug pipeline. A premium company. Earnings growth should be 20% plus.
PAST TOP PICK
(Was a top pick on June 14 down 5%) Has the best patent protection folio. Should grow 25% in 2002 and 15% for the next two years.
TOP PICK
They have a good product line plus good new product development is excellent. Very cheap now.
BUY
Good pipeline. Likes the price.
TOP PICK
Likes the pharmaceutical sector. Has a good pipeline for its drugs.
BUY
Likes the sector. Well positioned. Prefers over Merc.
PAST TOP PICK
(Was a top pick on Sept 26 up 3.5%) Will have to buy some biotechs to keep their pipelines growing.
PAST TOP PICK
(Was a top pick on Sept 10 up 4.4%) Not the best time to buy pharmaceuticals. Buy under $40.
DON'T BUY
Very expensive. US drug companies are having problems.
TOP PICK
Good cash flow. Will grow 20% + 2002/03 and 15% 2004. A good price.
BUY
Excellent company. Good dividends.
DON'T BUY
Great company, but economy is hitting all drug companies. Too high now.
Showing 826 to 840 of 883 entries